Xtant Medical price target lowered to $1.50 from $1.70 at Craig-Hallum

Craig-Hallum lowered the firm’s price target on Xtant Medical (XTNT) to $1.50 from $1.70 and keeps a Buy rating on the shares. While the firm remains excited about the potential of new product launches, the company will need to work its way through some third party inventory before utilizing internally sourced viable bone matrix with its distributors, which will take several quarters and delay the material gross margin benefit the firm had modeled into next year, the analyst tells investors.